Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Who Are Candidates for Genomic Testing

NCT02625935 is registered in ClinicalTrials.gov with NanoString Technologies, Inc. as lead sponsor.

NCT NCT02625935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02625935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Who Are Candidates for Genomic Testing
Lead sponsor
NanoString Technologies, Inc.
Phase
Observational
Overall status
Completed
Start date
December 31, 2015
Completion date
October 10, 2017
Enrollment
206 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer